Lilly's weight loss drug shortage deemed over

Competition will make weight-loss drugs better, cheaper and bigger
A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking remedies for erectile dysfunction and hair loss. Since May it has offered its own version of Wegovy,
Eli Lilly sues over knockoffs of signature weight loss drug, Zepbound
Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its weight-loss medicine Zepbound.
Lilly's weight loss drug shortage deemed over, but hurdles remain
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Eli Lilly Sues Over Knock-Off Weight-Loss Drugs
Eli Lilly has filed three new separate lawsuits accusing vendors and a medical spa of selling knock-off versions of their drug, Zepbound.
Lilly sues online vendors, medical spa over copycat weight-loss drugs
Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.
Weight Loss Drug Copies Face Legal Risk as FDA Reviews Shortage
Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions and legal challenges while the FDA reconsiders whether or not there is a shortage of the weight loss drug.
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Mangoceuticals To Defend Against Eli Lilly's Lawsuit Over Alleged Copying Of Weight-Loss Drugs
Mangoceuticals Inc. (MGRX) announced that Eli Lilly has made public allegations and filed a lawsuit against the company, claiming
Latest weight-loss drug faces shortages
The United States Food and Drug Administration (FDA) says that high demand has left the latest weight-loss drug, Zepbound, in short supply.
MangoRx hits back at Eli Lilly’s weight loss drug copycat claims
MangoRx was responding to Eli Lily after the drugmaker sued it and two other medical spas and online vendors earlier this week for selling products claiming to contain tirzepatide
Exclusive: Weight-loss drugs didn't curb health costs within two years, data show
Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...
KSL21h
Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds
Most U.S. states do not currently cover highly sought-after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...
The Financial Express1h
Data shows weight-loss drugs didn’t curb health costs within two years: Report
Prime Therapeutics reviewed pharmacy and medical claims data for 3,046 people with commercial health plans that cover GLP-1 ...